Lilly dustbins edivoxetine depression indication

Share this article:

Eli Lilly's Phase III test of edivoxetine for major depressive disorder is a fail. The company announced Thursday that the drug failed to surpass placebo when paired with a selective serotonin reuptake inhibitor (SSRI).

The company is dustbinning this indication, but ISI Group analyst Mark Schoenebaum wrote in his news assessment that Lilly may put the drug into the roster of possible ADHD therapies. Regardless, Schoenebaum writes Lilly's news won't upset Wall Street's opinion of the company. “Investors haven't exactly been optimistic that these Phase III trials would work, so today's news is not entirely surprising,” he writes.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.